Baloxavir Marboxil Intermediate (CAS 1228258-40-9)?
Google Keywords: Baloxavir Intermediate, CAS 1228258-40-9, Antiviral API Synthesis, Influenza Drug Intermediates, GMP Pharmaceutical Manufacturing

?? ?Product Overview?

?Baloxavir Marboxil Intermediate? (CAS 1228258-40-9) is a high-purity chemical intermediate crucial for synthesizing ?Baloxavir Marboxil?, a cap-dependent endonuclease inhibitor approved for treating influenza A and B infections. This intermediate ensures precision and scalability in antiviral API production, meeting stringent pharmaceutical quality standards.

• ?Primary Function?: Acts as a key building block in the synthesis of Baloxavir Marboxil API, enabling targeted antiviral activity.

• ?Applications?: Influenza drug development, antiviral manufacturing, and large-scale API production.

? ?Key Advantages?

?? ?Ultra-High Purity? | ≥99.0% (HPLC/GC verified) | Complies with ICH Q11 guidelines for intermediates.
?? ?Scalable Synthesis? | Optimized for high-yield production with minimal impurities, reducing time-to-market.
?? ?Regulatory Compliance? | Fully characterized by NMR, HRMS, and FTIR to support FDA/EMA submissions and GMP audits.

?? ?Applications?

1. ?API Production?: Enables efficient synthesis of Baloxavir Marboxil with consistent batch-to-batch quality.

2. ?Process Optimization?: Facilitates R&D in refining synthetic pathways for cost-effective manufacturing.

3. ?Quality Control?: Used in analytical method validation and stability testing during batch release.

?? ?Quality Assurance?

• ?Testing Methods?: HPLC, GC, NMR, HRMS, and FTIR for structural confirmation and purity analysis.

• ?Standards?: Meets USP <1086>, EP 10.0, and ISO 9001:2015 certified manufacturing protocols.

?? ?Market Trends?

The ?global antiviral drugs market? is projected to grow at a ?CAGR of 3.8%?, reaching ?$78.5 billion by 2030?, driven by rising influenza outbreaks and demand for single-dose therapies like Baloxavir. This intermediate is vital for accelerating generic and novel antiviral drug development post-patent expiry.

Elevate your influenza drug production with Baloxavir Intermediate – engineered for purity, scalability, and regulatory excellence.